Eledon Pharmaceuticals Inc (ELDN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Eledon Pharmaceuticals Inc stock (ELDN) is currently trading at $2.92. Analyst consensus price target for ELDN is $8.00. WallStSmart rates ELDN as Sell.
- ELDN PE ratio analysis and historical PE chart
- ELDN PS ratio (Price-to-Sales) history and trend
- ELDN intrinsic value — DCF, Graham Number, EPV models
- ELDN stock price prediction 2025 2026 2027 2028 2029 2030
- ELDN fair value vs current price
- ELDN insider transactions and insider buying
- Is ELDN undervalued or overvalued?
- Eledon Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ELDN Piotroski F-Score and Altman Z-Score
- ELDN analyst price target and Smart Rating
Eledon Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Eledon Pharmaceuticals Inc (ELDN) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Eledon Pharmaceuticals Inc (ELDN) Key Strengths (1)
61.23% held by institutions, strong professional interest
Supporting Valuation Data
Eledon Pharmaceuticals Inc (ELDN) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 6.5x book value
Micro-cap company with very limited liquidity and high volatility
Eledon Pharmaceuticals Inc (ELDN) Detailed Analysis Report
Overall Assessment
This company scores 11/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Price/Book, Market Cap. Some valuation metrics including Price/Book (6.47) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -35.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -35.80% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ELDN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ELDN's Price-to-Sales ratio of 1605.87x trades 34% below its historical average of 2436.8x (33th percentile). The current valuation is 84% below its historical high of 9840.94x set in Jan 2021, and 105% above its historical low of 783.03x in Nov 2023. Over the past 12 months, the PS ratio has compressed from ~2223.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Eledon Pharmaceuticals Inc (ELDN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Eledon Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -14M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Eledon Pharmaceuticals Inc.
Bottom Line
Eledon Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Eledon Pharmaceuticals Inc(ELDN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.